{"organizations": [], "uuid": "31020eeb418d433c226c90a47a89005e108b19ec", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180214.html", "section_title": "Archive News &amp; Video for Wednesday, 14 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-vertex-says-mid-stage-study-testin/brief-vertex-says-mid-stage-study-testing-pain-relief-drug-met-main-goal-idUSFWN1Q4198", "country": "US", "domain_rank": 408, "title": "BRIEF-Vertex Says Mid Stage Study Testing Pain Relief Drug Met Main Goal", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.817, "site_type": "news", "published": "2018-02-14T22:52:00.000+02:00", "replies_count": 0, "uuid": "31020eeb418d433c226c90a47a89005e108b19ec"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-vertex-says-mid-stage-study-testin/brief-vertex-says-mid-stage-study-testing-pain-relief-drug-met-main-goal-idUSFWN1Q4198", "ord_in_thread": 0, "title": "BRIEF-Vertex Says Mid Stage Study Testing Pain Relief Drug Met Main Goal", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "vertex", "sentiment": "negative"}, {"name": "vertex pharmaceuticals inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "vertex pharmaceuticals", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 14 (Reuters) - Vertex Pharmaceuticals Inc:\n* VERTEX ANNOUNCES TREATMENT WITH THE NAV1.8 INHIBITOR VX-150 SHOWED SIGNIFICANT RELIEF OF ACUTE PAIN IN PHASE 2 STUDY\n* VERTEX PHARMACEUTICALS - VX-150 WAS GENERALLY WELL TOLERATED AND SHOWED STATISTICALLY SIGNIFICANT RELIEF OF ACUTE PAIN COMPARED TO PLACEBO IN STUDY\n* VERTEX PHARMACEUTICALS INC - VERTEX ADVANCES ADDITIONAL NAV1.8 INHIBITOR, VX-128, INTO CLINICAL DEVELOPMENT\n* VERTEX PHARMACEUTICALS INC - THERE WERE NO DISCONTINUATIONS FOR ADVERSE EVENTS IN ANY ARM OF STUDY\n* VERTEX PHARMACEUTICALS INC - STUDY MET ITS PRIMARY ENDPOINT Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-14T22:52:00.000+02:00", "crawled": "2018-02-15T20:35:46.012+02:00", "highlightTitle": ""}